The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AMGN | +20.81% | +85.99% | +13.2% | +384,915% |
| S&P | +20.12% | +68.19% | +10.95% | +3,994% |
One of the pioneers of the biotech industry, Amgen is now one of the world's largest pharmaceutical companies, with more than a dozen products focused on cancer, inflammation, neurology, cardiology, and more.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $9.90B | 9.4% |
| Gross Profit | $8.11B | 8.0% |
| Gross Margin | 81.91% | -1.1% |
| Market Cap | $176.25B | 25.8% |
| Market Cap / Employee | $5.60M | 0.0% |
| Employees | 31.5K | 12.5% |
| Net Income | $1.33B | 112.6% |
| EBITDA | $5.07B | -4.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.13B | -23.8% |
| Accounts Receivable | $9.57B | 41.1% |
| Inventory | 6.2K | -11.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $50.70B | -11.4% |
| Short Term Debt | $4.73B | 29.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 8.45% | 4.1% |
| Return On Invested Capital | 12.69% | -2.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $961.00M | -78.2% |
| Operating Free Cash Flow | $1.60B | -66.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 28.44 | 22.84 | 21.82 | 23.00 | -33.42% |
| Price to Book | 28.46 | 24.19 | 20.45 | 18.32 | -1.55% |
| Price to Sales | 4.97 | 4.35 | 4.26 | 4.84 | 13.80% |
| Price to Tangible Book Value | -4.13 | -3.93 | -4.24 | -5.47 | 56.51% |
| Price to Free Cash Flow TTM | 28.04 | 26.83 | 23.56 | 59.72 | 135.13% |
| Enterprise Value to EBITDA | 86.54 | 49.99 | 51.31 | 44.15 | 23.70% |
| Free Cash Flow Yield | 3.6% | 3.7% | 4.2% | 1.7% | -57.47% |
| Return on Equity | 105.7% | 99.1% | 81.7% | 106.1% | 57.07% |
| Total Debt | $57.38B | $56.20B | $54.59B | $55.44B | -8.94% |
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
Its size, catalog, and pipeline give it strengths that are hard to beat.
The failed attempt to repeal and replace Obamacare last month has big implications for healthcare investors.
In this Valentine's Day edition, Industry Focus explores cholesterol busters, heart surgery, and the latest in anticoagulants.
AMGN earnings call for the period ending December 31, 2024.
AMGN earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
